World Investment Advisors LLC Sells 4,803 Shares of Sanara MedTech Inc. (NASDAQ:SMTI)

World Investment Advisors LLC decreased its position in shares of Sanara MedTech Inc. (NASDAQ:SMTI) by 18.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,112 shares of the company’s stock after selling 4,803 shares during the period. World Investment Advisors LLC owned 0.24% of Sanara MedTech worth $638,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Geode Capital Management LLC increased its position in Sanara MedTech by 4.4% during the third quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock worth $2,670,000 after acquiring an additional 3,755 shares during the period. State Street Corp raised its holdings in shares of Sanara MedTech by 9.2% in the third quarter. State Street Corp now owns 58,688 shares of the company’s stock valued at $1,775,000 after buying an additional 4,932 shares during the last quarter. Finally, Barclays PLC lifted its holdings in Sanara MedTech by 323.0% during the 3rd quarter. Barclays PLC now owns 5,731 shares of the company’s stock worth $174,000 after buying an additional 4,376 shares in the last quarter. 8.10% of the stock is owned by institutional investors and hedge funds.

Sanara MedTech Stock Performance

Sanara MedTech stock opened at $33.83 on Tuesday. The company’s 50-day moving average is $34.50 and its two-hundred day moving average is $32.03. The company has a market cap of $295.67 million, a PE ratio of -34.17 and a beta of 1.57. Sanara MedTech Inc. has a 1 year low of $26.00 and a 1 year high of $43.25. The company has a current ratio of 2.23, a quick ratio of 2.02 and a debt-to-equity ratio of 0.76.

Sanara MedTech (NASDAQ:SMTI) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.28. The company had revenue of $21.67 million during the quarter. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%. During the same period last year, the company earned ($0.13) earnings per share. Equities analysts anticipate that Sanara MedTech Inc. will post -1.42 earnings per share for the current year.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.